Abcam announces strong start to the new financial year
Abcam plc, a global leader in the supply of life science research tools, is holding its Annual General Meeting this morning.
At the meeting Murray Hennessy, Abcam’s Chairman, will make the following statement: “Following a successful 2014/15 I am pleased to say that the current year has started well and we have confidence in our ability to achieve the financial and strategic targets we have set for ourselves over the coming year.
"The positive momentum we reported in the last financial year has continued, which gives us confidence in the capital and operational investments we are making in the business. These will increase in the first half of the financial year; particularly given the higher run rate coming into the year, and the planned investment in Firefly BioWorks, which was acquired in January 2015. Our aim is to ensure that we are able to capitalise fully on the further opportunities available to us, whilst meeting our year-end financial targets.
"In addition, as previously announced, we are investing to build a scalable and flexible IT platform that fits the needs of Abcam today and tomorrow. We are at the design and system selection phase of a two to three year project and will provide further information on our investment plans as they progress.”
For further information please contact:
+ 44 (0) 1223 696 000
Alan Hirzel, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
J.P.Morgan Cazenove - Nominated Adviser & Corporate Broker
+ 44 (0) 20 7742 4000
James Mitford / Alex Bruce - Nominated Adviser
+44 (0) 20 3727 1000
Ben Atwell / Brett Pollard / Natalie Garland-Collins
As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster.